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Chronic myeloid leukemia (CML) is a myeloproliferative
disorder, characterized by the presence of the Philadelphia
(Ph) chromosome, a consequence of a reciprocal translocation
between chromosomes 9 and 22, resulting in the fusion of the
genes BCR and ABL. The BCR–ABL fusion gene encodes a
constitutively active leukemogenic protein tyrosine kinase.
BCR–ABL kinase activity is inhibited by the selective activity
of imatinib, a target agent that has demonstrated remarkable
efﬁcacy and tolerability.
1 It has been shown that imatinib blocks
cell proliferation and induces apoptosis in BCR–ABL-expressing
hematopoietic cells. Imatinib has been used as a ﬁrst line
therapy for CML patients.
2 Different patterns of response to
imatinib treatment have been recognized, ranging from best-
case scenarios of rapid and unwavering response to difﬁcult
situations of intolerance and resistance, either primary or
secondary.
3 In general, most patients under imatinib achieve a
major or complete cytogenetic response (CCyR), with restora-
tion of a Ph-negative hematopoiesis. However, recently, some
studies showed the appearance of clonal chromosomal
abnormalities in patients with Ph-negative cells under imatinib
treatment.
4–7 In this study, we describe four cases of CML
patients treated with imatinib. These patients showed cytoge-
netic response with the disappearance of Ph-positive cells, but
they acquired other clonal chromosomal abnormalities. In three
cases, we had an extra chromosome Y and, in one case, the
trisomy of 8. To our knowledge, this is the ﬁrst study that
discusses the acquisition of an extra chromosome Y in patients
treated with imatinib who had cytogenetic response.
Between 2000 and 2010 we studied, cytogenetically and
clinically, 100 patients with CML, who were treated with
imatinib at National Cancer Institute, Rio de Janeiro, Brazil. At
the beginning of the therapy with imatinib, 66 patients were in
chronic phase (CP), 24 patients in accelerated phase (AP) and 10
in blast crisis (BC). These patients were previously treated with
hydroxyurea and interferon-a. There were 57 males and 43
females. The mean age of our patients were 48 years old (range
from 14 to 75 years old). These patients were monitored by
cytogenetic and molecular analyses during the treatment with
imatinib. This study was reviewed and approved by the Ethical
Committee from National Cancer Institute and it was in
accordance with the Helsinki Declaration of 1975.
Karyotypes of bone marrow cells were obtained from cultures
in RPMI 1640 with 20% fetal calf serum at 371C for 24h. Cell
cultures were pulsed with colcemid. Cells were subsequently
harvested by standard procedures and ﬁxed in methanol-acetic
acid. The chromosomes were analyzed by G-banding. The
cytogenetic response was deﬁned by the percentage of cells in
metaphase, which was positive for the Ph chromosome in the
bone marrow.
1 Fluorescence in situ hybridization (FISH)
analysis was applied to ﬁxed cell suspensions. We used the
probes: LSI BCR/ABL1 dual-color, single-fusion probe; LSI
c-myc (8q24.12-q24.13) (Vysis, Abbott Molecular, Des Plaines,
IL, USA) and LPE 0YqR (Cytocell, Cambridge, UK). FISH was
performed according to the recommendations of the manufac-
tures. The molecular analysis was done to investigate the
presence of the fusion transcripts (b3a2 or b2a2), using reverse
transcription (RT)-PCR and nested PCR in diagnosis. During the
treatment, it was also performed the real-time RT-PCR.
We did statistical analysis to show that the presence of
Ph chromosome, as sole chromosomal abnormality, is signiﬁ-
cantly higher in patients at CP than in patients at AP and BC. We
also proved statistically that the inﬂuence of Ph chromosome as
sole chromosomal abnormality is higher in the cytogenetic
response of patients treated with imatinib, compared with the
inﬂuence of Ph chromosome with additional abnormalities.
Po0.01 was considered signiﬁcant in all analyses.
One hundred patients with CML were studied cytogenetically
and clinically during the treatment with imatinib. Among these
patients, 74 had the Ph chromosome as sole chromosomal
abnormality (74%) and 26 had Ph chromosome and additional
chromosomal abnormalities (26%) before beginning the treat-
ment. Patients only with Ph chromosome before the treatment
were more frequently in CP than in AP and BC (81% versus
19%, Po0.001). Also, the patients with only the Ph-positive
cells had a signiﬁcant higher rate of major cytogenetic response
than the patients with Ph and additional chromosomal
abnormalities (90% versus 10%, Po0.001). Based on clinical
results from randomized trials, imatinib is approved for all
phases of CML, but best results of this treatment is observed in
CML patients at the initial phase of the disease, as observed in
our study and others.
8
From the total of 100 patients studied, we observed the
appearance of clonal chromosomal alterations during
the imatinib treatment in four cases. The chromosome Ph was
the only karyotypic abnormality. The molecular analysis
showed the presence of the fusion transcripts: b2a2 in patients
1, 2 and 3; the b3a2 in patient 4. The patients were in CP and
they received 400mg per day of imatinib after interferon-a
resistance/intolerance. After the patients had achieved a CCyR,
with Ph-negative cells, which was observed by G-banding and
FISH analysis, it was detected the presence of clonal cytogenetic
abnormalities. Three patients showed the gain of chromosome Y
(Figure 1) and one patient acquired trisomy 8. The patients
achieved hematologic, cytogenetic and molecular responses.
They showed no clinical symptoms of CML and the imatinib
treatment was continued. The mean survival of these four
patients was 60 months, since the imatinib treatment had been
started. The clinical, cytogenetic and molecular characteristics
of the four patients are shown in Table 1.
A cytogenetic phenomenon that has showed considerable
interest in the present era of imatinib treatment is the
appearance of clonal cytogenetic alterations in Ph-negative
cells, which frequency varies greatly, ranging from 2 to 15%.
4
In our study, this frequency was 4%. The mean time of
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after imatinib therapy started. A review of the literature showed
that this period may vary from 3 to 47 months.
4 The most
common changes observed in Ph-negative cells are:  7, þ8,
 5 and  Y. Such changes are also presented in myelodysplastic
syndromes (MDS) and acute myeloid leukemia (AML), which
has raised concerns about their clinical implication. The
frequency of MDS/AML in such patients is in order of 2–
10%.
9–11 Analyzing the bone marrow of our four patients, they
did not show the morphologic features of MDS/AML. Lin et al.
6
also showed no association with MDS/AML. Jabbour et al.
7
suggested that patients with CML require continued monitoring
with cytogenetic analysis, but in the absence of additional
clinical complications (for example, trilineage dysplasia) a
change in treatment strategy is not necessarily indicated.
In our study, we observed an acquisition of an extra
chromosome Y in three cases and in one case the trisomy 8.
The trisomy 8 is well documented in the literature. Nevertheless,
an extra chromosome Y is a rare phenomenon in leukemia. It
was described by Watanabe et al.
12 in one case of T-cell acute
lymphoblastic leukemia, as a sole chromosome abnormality and
the patient achieved complete remission by chemotherapy.
Interesting, Deininger et al.
4 studied 532 patients with CML
treated with imatinib. They related that the most frequently
involved chromosomes were Y and 8 in cases with Ph-negative
cells in response to imatinib, with a frequency of 37% and 27%,
respectively.
4 But, Deininger et al.
4 also detected an extra
chromosome Y in three CML patients with Ph-negative cells in
response to imatinib treatment. Nevertheless, these ﬁndings
were not yet discussed in the literature, as most cases with the
involvement of chromosome Y are related to loss of this
chromosome and not the gain. The loss of the chromosome Y
in hematologic neoplasms is frequently associated with a
favorable prognosis.
4,13 Although, Lippert et al. related that
the loss of Y chromosome in Ph-positive cells predicts a poor
response of CML patients to imatinib therapy.
14 These ﬁndings
raise the question: Which genes are localized in Y chromosome
that may be associated with imatinib response? Analyzing the
genes localized in chromosome Y we can ﬁnd: SRY (sex
determining region Y), TGIF2Ly (TGFB-induced factor homeo-
box 2-like), PCDH11Y (protocadherin 11), PRKY (protein
kinase), TSPY 1 (testis-speciﬁc protein), USP9Y (ubiquitin-
speciﬁc peptidase 9), DDX3Y (DEAD box polypeptide 3),
CD24 (CD24 molecule), RBMY1A1 (RNA-binding motif
protein).
15 It may be possible that some of these genes, such
as: TGIF2Ly, PRKY, RBMY1A1, may be inﬂuencing the
Figure 1 (a) Interphase-FISH (I-FISH) showing Ph-positive cells before imatinib treatment. (b) I-FISH showing Ph-negative cells under imatinib
therapy. (c) G-banding showing the karyotype of bone marrow cell: 47,XY,þY. (d) I-FISH using the probe LPE 0Yq/R showing two signals for Y
chromosome.
Table 1 Clinical, cytogenetic and molecular characteristics of the four patients with clonal chromosomal abnormalities in Ph-negative cells
during imatinib therapy
Diagnosis Imatinib treatment
Patient Sex/age
(years)
Peripheral blood counts Cytogenetic
analysis
Molecular
analysis
CCyR
(months)
Cytogenetic
alterations in
Ph-negative cells
Time of
detection
(months)
Status
(follow-up,
in months)
Hb
(g/dl)
Leukocytes
 10
3/mm
3
Platelets
 10
3/mm
3
G-banding Nested PCR
1 M/36 7.97 106 409 46,XY,t(9;22)(q34;q11)[25] b2a2 6 47,XY,+Y[5]/46,XY[25] 72 Alive (84)
2 M/35 10.2 89.9 676 46,XY,t(9;22)(q34;q11)[20] b2a2 12 47,XY,+Y[6]/46,XY[19] 44 Alive (72)
3 M/57 13.4 42.7 531 46,XY,t(9;22)(q34;q11)[51] b2a2 12 47,XY,+Y[3]/46,XY[17] 48 Alive (60)
4 F/47 9.0 83.8 348 46,XX,t(9;22)(q34;q11)[20] b3a2 15 47,XX,+8[10]/46,XX[10] 21 Alive (24)
Abbreviations: CCyR, complete cytogenetic response; F, female; Hb, hemoglobin; M, male.
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candidates of future studies.
Despite the increased number of reports of Ph-negative
clones, the signiﬁcance and potential causes for Ph-negative
clonal cytogenetic abnormalities in hematopoiesis remain
unclear. Some studies associated the development of clonal
cytogenetic abnormalities by previous treatment like hydro-
xyurea or IFN-a. Nevertheless, some studies have been shown
the clonal cytogenetic alterations in larger series of patients
receiving only imatinib treatment.
7 But, in fact, more studies
with longer follow-up in larger patient cohorts are necessary to
enable researchers to answer the signiﬁcance of the acquired
clonal chromosome abnormalities during imatinib therapy, their
correlation into the basic CML pathogenesis and their clinical
impact.
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